News & Updates

Remdesivir and favipiravir does not appear to be heart-friendly in patients with COVID-19, according to a study presented at APSR 2023.

A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.

Most older adults living in Singapore have good knowledge of the common symptoms of COVID-19 and awareness of government-endorsed preventive measures, according to a recent study.

Patients with coronavirus disease-2019 (COVID-19) commonly present with headaches, loss of smell and taste, diarrhea, and breathing difficulties.